| scholarly article | Q13442814 |
| editorial | Q871232 |
| P2093 | author name string | Masatoshi Kudo | |
| P2860 | cites work | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 |
| Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. | Q45020373 | ||
| Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial | Q47376936 | ||
| Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. | Q47788877 | ||
| Lenvatinib in Advanced Hepatocellular Carcinoma | Q49884642 | ||
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Q50046367 | ||
| SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. | Q50454368 | ||
| Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. | Q55072288 | ||
| Hepatocellular carcinoma | Q57756376 | ||
| Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial | Q57762740 | ||
| Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma | Q73924235 | ||
| Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma | Q85049476 | ||
| Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial | Q88310077 | ||
| Modes of resistance to anti-angiogenic therapy | Q24608005 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial | Q29617955 | ||
| Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 | ||
| Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage | Q34144848 | ||
| Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma | Q34151946 | ||
| Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models | Q34253418 | ||
| Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma | Q34647911 | ||
| Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening | Q34701235 | ||
| Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 | ||
| Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma | Q35821594 | ||
| FGFR4 and TGF-β1 expression in hepatocellular carcinoma: correlation with clinicopathological features and prognosis | Q37376265 | ||
| Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma | Q37710134 | ||
| Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. | Q37832895 | ||
| Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy | Q38087230 | ||
| Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design | Q38192888 | ||
| Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). | Q38613018 | ||
| Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. | Q38711169 | ||
| Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses | Q38754388 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. | Q38993647 | ||
| mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib | Q39032512 | ||
| Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials | Q39043076 | ||
| Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma | Q39179262 | ||
| Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study | Q39979280 | ||
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Q40231174 | ||
| FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. | Q41108851 | ||
| Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma | Q41187204 | ||
| Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now? | Q42169289 | ||
| Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives | Q42317924 | ||
| Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma | Q42380812 | ||
| Why does every hepatocellular carcinoma clinical trial using molecular targeted agents fail? | Q42560671 | ||
| P433 | issue | 1 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 1-19 | |
| P577 | publication date | 2018-02-15 | |
| P1433 | published in | Liver cancer | Q26842090 |
| P1476 | title | Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma | |
| P478 | volume | 7 |
| Q95276807 | Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging |
| Q98946761 | Better Efficacy of Ramucirumab in Japanese Patients than in the Global Population with Unresectable Hepatocellular Carcinoma |
| Q97543832 | Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma |
| Q90694493 | Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment |
| Q92735228 | Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy |
| Q64955584 | Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy. |
| Q92876631 | Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies |
| Q91942647 | Implications of Immunotherapy in Hepatobiliary Tumors |
| Q57793260 | Increased Expression of Lysine-Specific Demethylase 5B (KDM5B) Promotes Tumor Cell Growth in Hep3B Cells and is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma |
| Q100533703 | Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib |
| Q92343733 | Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study |
| Q61805290 | Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date |
| Q92486987 | Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells |
| Q64068635 | LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells |
| Q59349475 | Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion: A case report |
| Q94603196 | Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib |
| Q91879742 | Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial |
| Q58093758 | Systemic Therapy for Hepatocellular Carcinoma: Latest Advances |
| Q64122405 | Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond |
| Q64114256 | Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib |
| Q64070965 | The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma |
Search more.